AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12802644
Drug: Isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride solution (Group B)
Trial: 30741682
Drug: Cerebral amyloid-β
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebral amyloid-β (Aβ) deposition measured by 11C Pittsburgh compound B (PIB) PET scan
Trial: 29626614
Drug: Whole Body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Body Vibration (WBV) intervention (3.6‐11.6 g), 3 times per week for 6 months
Trial: 10632642
Drug: Alosetron 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 2 mg b.d.
Trial: 9768527
Drug: Alosetron 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 4 mg b.d.
Trial: 10468696
Drug: Alosetron 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 8 mg b.d.
Trial: 345889
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release theophylline preparation
Trial: 30739369
Drug: Topical gaseous
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical gaseous ozone applied into periodontal pockets twice a week for 2 weeks during active periodontal therapy
Trial: 25370147
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (40 IU/1 mL)
Trial: 24835171
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg orally)
Trial: 17613399
Drug: Basiliximab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (20 mg on Day 0 and Day 4)
Trial: 17613399
Drug: Anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-thymocyte globulin (ATG, 2.5 mg/kg/day for 3 to 5 days)
Trial: 8130287
Drug: Group physical
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group physical therapy (weekly for 9 months)
Trial: 2446574
Drug: Aprotinin (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (high doses to achieve plasma concentrations of more than 150 kallikrein inactivator units per milliliter)
Trial: 29619453
Drug: Supervised exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exposure to one standard erythemal dose (SED; 100 J m‐2) of solar UV radiation three days per week for three weeks
Trial: 20199828
Drug: Energy-protein supplements
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-protein supplements (40 g of protein and 400 kcal per day)
Trial: 17469678
Drug: Newer disease-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer disease-modifying approaches such as immunotherapy
Trial: 15670038
Drug: no GPIIb-IIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no GPIIb-IIIa antagonist (control)
Trial: 11034258
Drug: Sirolimus (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (1 mg/m2)
Trial: 11034258
Drug: Sirolimus (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (3 mg/m2)
Trial: 11034258
Drug: Sirolimus (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (5 mg/m2)
Trial: 24807871
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (OMP)
Trial: 26512775
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol with sequential OMP
Trial: 26512775
Drug: CEE/E/E2+cyclic OMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE/E/E2+cyclic OMP at 200 mg/day
Trial: 9049690
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no tamoxifen treatment)
Trial: 8447209
Drug: Doxapram 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram 1.8 mg.kg‐1.h‐1
Trial: 28404108
Drug: 16 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 weeks of treatment with ombitasvir (25 mg), paritaprevir (150 mg), ritonavir (100 mg) plus weight-based ribavirin dosed twice daily
Trial: 18245406
Drug: 24% oral
RxNorm normalized name: Entero VU, 24% oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% oral sucrose and pacifier
Trial: 15871555
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart (BIAsp30)
Trial: 10355516
Drug: Rebamipide (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide (oral, 300 mg/day for 3 weeks starting 1 week before TAE)
Trial: 7794594
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment with ambulatory and domiciliary care
Trial: 7023307
Drug: Chenodiol 750
RxNorm normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodiol 750 mg/d
Trial: 7023307
Drug: Chenodiol 375
RxNorm normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodiol 375 mg/d
Trial: 31683467
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg for 15 min before incision, followed by 0.3‐0.5 μg/(kg·h) till the end of the operation)
Trial: 22616830
Drug: DrotAA (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DrotAA (24 μg/kg/hour) for 96 hours
Trial: 22616830
Drug: DrotAA (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DrotAA (24 μg/kg/hour) for 96 hours in patients with severe protein C deficiency
Trial: 12757987
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin
Trial: 17634053
Drug: Treatment Optimization
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Optimization Program (TOP) tool
Trial: 16372518
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate (20 mg metal zinc)
Trial: 9657654
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 1600 microg daily for 2 months
Trial: 7814824
Drug: Eliprodil 30
RxNorm normalized name: Eliprodil
DrugBank: Eliprodil (DB12869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliprodil 30 mg
Trial: 7814824
Drug: Midazolam 15
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 15 mg (positive control)
Trial: 30229939
Drug: SQ tree
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ tree SLIT-tablet (12 DU)
Trial: 22770920
Drug: 1200mg oral
RxNorm normalized name: FISH OIL 1200MG ORAL CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200mg oral gabapentin
Trial: 20109575
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue 1 mg/kg
Trial: 20109575
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue 3 mg/kg
Trial: 20109575
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue 7 mg/kg
Trial: 20109575
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (all doses)
Trial: 20109575
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (high doses)
Trial: 18664347
Drug: Tanreqing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanreqing injection (20 ml, once daily for 10 days)
Trial: 18664347
Drug: Ambroxol hydrochloride
RxNorm normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol hydrochloride injection (15 mg, twice daily for 10 days)
Trial: 25632741
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (control group)
Trial: 18664347
Drug: Tanreqing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanreqing injection
Trial: 18664347
Drug: Ambroxol hydrochloride
RxNorm normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol hydrochloride injection
Trial: 15856479
Drug: Daclizumab (DZB)
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab (DZB) induction and daily mycophenolate mofetil with steroids
Trial: 15856479
Drug: Standard tacrolimus-based
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tacrolimus-based triple therapy
Trial: 1827074
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 2 mg + 35 micrograms ethinyl estradiol
Trial: 10543928
Drug: ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril 5 mg/day
Trial: 17763588
Drug: Midazolam dissolved
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam dissolved in glucose solution (n = 50)
Trial: 17763588
Drug: Glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solution only with communication technique (n = 50)
Trial: 15530676
Drug: Varicella vaccine
RxNorm normalized name: Varicella vaccine
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varicella vaccine (Varilrix)
Trial: 11354528
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of melatonin
Trial: 9602585
Drug: Methoxamine 10
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxamine 10 mg i.m. (group MX)
Trial: 9602585
Drug: 6% hetastarch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hetastarch 500 ml and crystalloid 500 ml (group HS)
Trial: 2275207
Drug: Rumalon-injections
RxNorm normalized name: Rumagon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rumalon-injections
Trial: 29777234
Drug: Low dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dairy products (≤600 mg calcium/day)
Trial: 28127938
Drug: Crushed naloxegol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed naloxegol 25-mg tablets (suspended in water) administered orally
Trial: 28127938
Drug: Crushed naloxegol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed naloxegol 25-mg tablets (suspended in water) administered by nasogastric tube
Trial: 28127938
Drug: Naloxegol solution
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Naloxegol solution
Trial: 28127938
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available 25-mg tablet formulation
Trial: 24549209
Drug: New method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New method of suspension
Trial: 24549209
Drug: Conventional suction
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional suction suspension
Trial: 19411357
Drug: Standard evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard evidence-based treatment protocol
Trial: 9744490
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 320 mg
Trial: 26035253
Drug: ABT-639 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-639 (100 mg oral dose)
Trial: 9113633
Drug: High-AA diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-AA diet (1.5 g/d of additional 20:4n‐6)
Trial: 9113633
Drug: Low-AA diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-AA diet (210 mg/d of 20:4n‐6)
Trial: 8187319
Drug: rhIGF‐I administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I administered subcutaneously in a dose of 40 micrograms/kg body weight
Trial: 31148412
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg administered in fasting state
Trial: 31148412
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg administered in fed state
Trial: 19654233
Drug: PEG-GH (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-GH (1 mg for 3 weeks, then 2 mg for 3 weeks)
Trial: 19654233
Drug: PEG-GH (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-GH (4 mg for 3 weeks, then 8 mg for 3 weeks)
Trial: 19654233
Drug: PEG-GH (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-GH (4 mg for 6 weeks)
Trial: 16966367
Drug: Capecitabine (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1250 mg/m(2) twice daily days 1-14) plus Docetaxel (75 mg/m(2) day 1)
Trial: 16966367
Drug: Reduced doses
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced doses of Capecitabine (950 mg/m(2)) and Docetaxel (55 mg/m(2))
Trial: 10670523
Drug: Electromotive drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromotive drug administration of the 3-drug association orgotein-dexamethasone-lidocaine (study 1)
Trial: 10670523
Drug: Electromotive drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromotive drug administration of the 2-drug combination verapamil-dexamethasone (study 2)
Trial: 9487787
Drug: Intercostal blocks
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal blocks (ICB) with 5 ml bupivacaine 0.5%
Trial: 9487787
Drug: Interpleural analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpleural analgesia (IPA) with 20 ml bupivacaine 0.25%
Trial: 29469337
Drug: Praziquantel (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (30 mg/(kg·d) for 2 days each year for three consecutive years)
Trial: 29469337
Drug: Conventional liver
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional liver protection therapy and symptomatic treatment
Trial: 20140619
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (7 days)
Trial: 12739705
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg o.d.
Trial: 16550734
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg b.i.d.
Trial: 10561618
Drug: Intra-amniotic (15S)-15-methyl-prostaglandin
RxNorm normalized name: 15(S)-15-Methyl Prostaglandin F2α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic (15S)-15-methyl-prostaglandin F2alpha (2.5 mg)
Trial: 10561618
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol (200 microg, two doses at 12-hour intervals)
Trial: 22421748
Drug: Adenovirus type
RxNorm normalized name: Adenovirus types 4 and 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenovirus type 5 (Ad5) vector‐based vaccine
Trial: 12909491
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone (GnRH) agonist treatment for 3 months before laparoscopic surgery
Trial: 12909491
Drug: Endometriotic stromal
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometriotic stromal cells obtained from patients with GnRH agonist treatment
Trial: 6290132
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g guar gum with 25 g D-xylose
Trial: 23435021
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) - Daily conjugated equine estrogens (0.625 mg) and medroxyprogesterone acetate (2.5 mg; EPT) or conjugated equine estrogens (0.625 mg; ET)
Trial: 15743112
Drug: Thioctic acid
RxNorm normalized name: Thioctic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioctic acid at an oral dosage of 800 mg/day for 4 months
Trial: 11064772
Drug: Oral cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cefuroxime axetil for 10 days
Trial: 11064772
Drug: Intramuscular benzathine
RxNorm normalized name: Cephapirin Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular benzathine penicillin (one dose)
Trial: 8364872
Drug: LC9018 combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC9018 combined with radiation therapy
Trial: 22310055
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy alone
Trial: 21892418
Drug: Problem-solving treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving treatment (PST)
Trial: 6397332
Drug: Spiramycin 500
RxNorm normalized name: spiramycin
DrugBank: Spiramycin (DB06145)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Spiramycin 500 mg 3-times daily for 3 days
Trial: 6397332
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg 3-times daily for 5 days
Trial: 30721586
Drug: Tolvaptan 15
RxNorm normalized name: tolvaptan 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 15 mg + Furosemide 20 mg (TH group)
Trial: 30721586
Drug: Tolvaptan 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan 7.5 mg + Furosemide 20 mg (TI group)
Trial: 23163605
Drug: Negative-restrictive slogans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-restrictive slogans (e.g., 'Don't drink')
Trial: 15671112
Drug: hCG (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG (10,000 IU, single IM injection on day 19)
Trial: 12025445
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy for children with IDA after a 3-month follow-up period.
Trial: 8600086
Drug: Sequential PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential PCI
Trial: 6179344
Drug: Oral retinoids
RxNorm normalized name: tocopheryl retinoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral retinoids in combination with bleomycin, cyclophosphamide, prednisone, and transfer factor
Trial: 6179344
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no retinoids, only chemotherapy with bleomycin, cyclophosphamide, and prednisone)
Trial: 11059999
Drug: Acute tryptophan
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute tryptophan depletion (induced by a 100 g amino acid drink following an overnight fast)
Trial: 9114915
Drug: Orlistat (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (80 mg) administered at mid-meal (group A)
Trial: 9114915
Drug: Orlistat (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (80 mg) administered 1 hour after mid-meal (group B)
Trial: 9114915
Drug: Orlistat (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (80 mg) administered 2 hours after mid-meal (group C)
Trial: 363751
Drug: Aspirin 650
RxNorm normalized name: aspirin 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 650 mg
Trial: 3540032
Drug: Ketorolac 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 5 mg
Trial: 31594895
Drug: Reminders from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminders from family members for adherence to antihypertensive medications.
Trial: 31594895
Drug: Awareness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Awareness of the names or purpose of their medications.
Trial: 29467829
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available non-surgical treatment (offloading cast applied for up to 12 weeks)
Trial: 24041199
Drug: Standardized disorder-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized disorder-specific Internet-based treatment (8 weeks)